Vanguard Fiduciary Trust
AVBP icon

Vanguard Fiduciary Trust’s ArriVent BioPharma AVBP Stock Holding History

Vanguard Fiduciary Trust’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.01M Buy
259,290
+42,163
+19% +$1.24M ﹤0.01% 1871
2026
Q1 		$5.01M Buy
+217,127
New +$4.9M ﹤0.01% 2076

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust's AVBP Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its ArriVent BioPharma (AVBP) stake by 19% in Q2 2026, buying an estimated $1.24M and bringing the position to 259,290 shares worth $9.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Vanguard Fiduciary Trust first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Vanguard Fiduciary Trust held 259,290 shares of ArriVent BioPharma worth $9.01M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 42,163 ArriVent BioPharma shares in Q2 2026, an estimated $1.24M.
  • ArriVent BioPharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1871 holding.
  • Vanguard Fiduciary Trust first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.